BeiGene Ltd is a clinical-stage biopharmaceutical company engaged in the discovery & development of molecularly targeted & immuno-oncology drugs for the treatment of cancer. Its product includes BGB-3111, BGB-283 and BGB-290 and one immuno-oncology agent. This is an ADR of a company whose stock trades outside of the U.S. as the symbol HK:6160.
$256.81 +1.76 (0.69%)
As of 02/03/2023 15:59:55 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.